Brachytherapy for prostate cancer (PCa) is associated with favorable 15-year cancer-specific survival, particularly in patients with high-risk disease, a study found. In addition, brachytherapy patients who receive hormone therapy for more than 6 months have decreased all-cause survival. Read the article.
Brachytherapy Offers Favorable Long-Term Prostate Cancer Survival Read More »
Targeted focal therapy (TFT) in carefully selected patients is a feasible and practical option for treating low-risk prostate cancer (PCa) with minimal impact on quality of life, researchers concluded. Read the article.
Focal Prostate Cancer Therapy Safe, Feasible Read More »
Three-fifths of men receiving permanent seed brachytherapy (BT) for localized prostate cancer (PCa) have preserved erectile function (EF) 5 years after seed implantation, according to researchers. Read the article.
Post-Brachytherapy Erectile Function Preserved in Most Men Read More »
Starting chemotherapy along with androgen deprivation therapy (ADT) in patients newly diagnosed with metastatic prostate cancer (mPCa) improved median overall survival by more than 13 months, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago. Read the article.
Chemo-ADT Combo Ups Survival in Patients with Metastatic PCa Read More »
May 2014 Scotiabank Awareness Night “Image-Guided Diagnosis and Treatment- The Future of Prostate Cancer has Arrived!” Dr. Andrew Loblaw MD, MSc, FRCSC Sunnybrook Health Sciences Centre Staff Radiation Oncologist, Odette Cancer Centre Associate Professor, Department of Radiation Oncology, University of Toronto Associate Professor, Department of Health Policy, Management and Evaluation, University of Toronto Courtesy Staff, Department of Surgery, North York General Hospital Surgical Oncology, Division of Urology, University Health Network Dr. Loblaw reviews the advantages of Magnetic Resonance Imaging (MRI) in the diagnosis and treatment of prostate cancer and the outcomes of image-guided radiation treatment for prostate cancer. He discusses the
Minimally invasive approach is promising for low-risk disease; outcomes data are lacking. Read the article.
Focal Therapy: Magic Bullet or Unproven Treatment Read More »
Robot-assisted radical prostatectomy (RARP) led to complication rates, readmission rates, and rates of additional cancer therapy similar to those of conventional surgical prostatectomy, a review of almost 6,000 cases showed. Read the article.
Robot Versus Surgeon: No Clear Winner Read More »
This site has a number of videos on early detection of metastatic prostate cancer. View them here.
Videos: Early Detection of Metastatic Prostate Cancer Read More »
Based on new research, men with localized prostate cancer but at high risk for metastasis, have better outcomes if they are treated with radiation combined with androgen deprivation therapy which decreases testosterone, thus reducing chance for tumor spread and growth. Read the article.